Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 10 | 2023 | 294 | 2.760 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 11 | 2020 | 180 | 1.650 |
Why?
|
| Brachytherapy | 7 | 2023 | 121 | 1.350 |
Why?
|
| Breast Neoplasms | 15 | 2021 | 2980 | 1.170 |
Why?
|
| Chemoradiotherapy | 5 | 2020 | 308 | 1.170 |
Why?
|
| Radiotherapy Dosage | 9 | 2023 | 471 | 0.880 |
Why?
|
| Radiation Injuries | 5 | 2021 | 160 | 0.860 |
Why?
|
| Human papillomavirus 18 | 1 | 2020 | 16 | 0.720 |
Why?
|
| Vaccines, DNA | 1 | 2020 | 18 | 0.720 |
Why?
|
| Endometrial Neoplasms | 3 | 2019 | 205 | 0.720 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 38 | 0.710 |
Why?
|
| Cell Hypoxia | 1 | 2020 | 170 | 0.680 |
Why?
|
| Safety | 1 | 2020 | 151 | 0.670 |
Why?
|
| Radiotherapy | 3 | 2016 | 331 | 0.630 |
Why?
|
| Radiometry | 2 | 2016 | 56 | 0.600 |
Why?
|
| Radiosurgery | 2 | 2021 | 280 | 0.590 |
Why?
|
| Cone-Beam Computed Tomography | 3 | 2020 | 63 | 0.510 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 253 | 0.470 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2016 | 176 | 0.450 |
Why?
|
| Radiation Oncology | 3 | 2019 | 121 | 0.440 |
Why?
|
| Radiotherapy, Conformal | 4 | 2020 | 84 | 0.440 |
Why?
|
| Female | 38 | 2023 | 45753 | 0.430 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1184 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2018 | 1094 | 0.410 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 319 | 0.410 |
Why?
|
| Mastectomy, Segmental | 3 | 2011 | 94 | 0.390 |
Why?
|
| Lymph Nodes | 2 | 2016 | 548 | 0.380 |
Why?
|
| Genital Neoplasms, Female | 2 | 2023 | 108 | 0.360 |
Why?
|
| Neoplasm Staging | 9 | 2021 | 1983 | 0.340 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 170 | 0.330 |
Why?
|
| Middle Aged | 24 | 2021 | 25698 | 0.330 |
Why?
|
| Dietary Supplements | 1 | 2010 | 130 | 0.330 |
Why?
|
| Sexism | 2 | 2019 | 52 | 0.330 |
Why?
|
| Humans | 41 | 2023 | 88601 | 0.320 |
Why?
|
| Biological Products | 1 | 2010 | 147 | 0.300 |
Why?
|
| Aged | 20 | 2019 | 18930 | 0.300 |
Why?
|
| Prostheses and Implants | 1 | 2007 | 125 | 0.290 |
Why?
|
| Prostate | 1 | 2010 | 392 | 0.270 |
Why?
|
| Bone and Bones | 1 | 2007 | 269 | 0.270 |
Why?
|
| Aged, 80 and over | 12 | 2018 | 6722 | 0.260 |
Why?
|
| Organs at Risk | 2 | 2016 | 41 | 0.260 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 1764 | 0.250 |
Why?
|
| Cisplatin | 3 | 2018 | 616 | 0.240 |
Why?
|
| Adult | 17 | 2021 | 26347 | 0.240 |
Why?
|
| Mammography | 1 | 2007 | 468 | 0.240 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2021 | 295 | 0.220 |
Why?
|
| Tumor Burden | 2 | 2017 | 304 | 0.210 |
Why?
|
| Heart | 3 | 2018 | 572 | 0.200 |
Why?
|
| Hysterectomy | 2 | 2020 | 150 | 0.190 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2021 | 58 | 0.190 |
Why?
|
| Treatment Outcome | 10 | 2019 | 8177 | 0.190 |
Why?
|
| Standard of Care | 1 | 2021 | 65 | 0.190 |
Why?
|
| Rectum | 3 | 2016 | 148 | 0.190 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 31 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 2536 | 0.180 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2020 | 34 | 0.180 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2019 | 49 | 0.180 |
Why?
|
| Oximetry | 1 | 2020 | 82 | 0.170 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 111 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 1111 | 0.170 |
Why?
|
| Dilatation | 1 | 2019 | 48 | 0.170 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 336 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 2638 | 0.170 |
Why?
|
| Breast | 2 | 2011 | 292 | 0.170 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 499 | 0.160 |
Why?
|
| Urethral Neoplasms | 1 | 2018 | 10 | 0.160 |
Why?
|
| Physicians, Women | 1 | 2019 | 56 | 0.160 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 218 | 0.160 |
Why?
|
| Postoperative Care | 2 | 2017 | 229 | 0.160 |
Why?
|
| Breath Holding | 1 | 2018 | 22 | 0.160 |
Why?
|
| Methylprednisolone | 1 | 2018 | 66 | 0.160 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2018 | 29 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 335 | 0.150 |
Why?
|
| Vagina | 1 | 2019 | 173 | 0.150 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 304 | 0.150 |
Why?
|
| Retrospective Studies | 9 | 2021 | 8892 | 0.150 |
Why?
|
| Thoracic Wall | 2 | 2014 | 25 | 0.150 |
Why?
|
| Young Adult | 5 | 2017 | 6217 | 0.150 |
Why?
|
| Colon, Sigmoid | 1 | 2016 | 6 | 0.140 |
Why?
|
| Deoxycytidine | 1 | 2018 | 238 | 0.140 |
Why?
|
| Polycythemia Vera | 1 | 2016 | 23 | 0.140 |
Why?
|
| Urinary Bladder | 2 | 2016 | 246 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2016 | 25 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 169 | 0.140 |
Why?
|
| Repressor Proteins | 1 | 2020 | 419 | 0.140 |
Why?
|
| Hydroxyurea | 1 | 2016 | 239 | 0.140 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 93 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2016 | 82 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 884 | 0.130 |
Why?
|
| Skin | 2 | 2016 | 581 | 0.130 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 2336 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 597 | 0.130 |
Why?
|
| Lung | 2 | 2014 | 1243 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2016 | 150 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 367 | 0.130 |
Why?
|
| United States | 5 | 2021 | 6882 | 0.130 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2014 | 2 | 0.130 |
Why?
|
| Oxygen | 1 | 2020 | 743 | 0.130 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 78 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1352 | 0.120 |
Why?
|
| Contrast Media | 1 | 2020 | 1088 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2021 | 846 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1709 | 0.120 |
Why?
|
| Radiation Dosage | 2 | 2012 | 226 | 0.120 |
Why?
|
| Patient Positioning | 1 | 2014 | 64 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1240 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 307 | 0.110 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 1213 | 0.110 |
Why?
|
| Equipment Design | 1 | 2014 | 416 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 299 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 379 | 0.110 |
Why?
|
| Surgical Instruments | 2 | 2014 | 59 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 181 | 0.100 |
Why?
|
| Radiodermatitis | 1 | 2011 | 10 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 103 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 661 | 0.100 |
Why?
|
| Trigeminal Neuralgia | 1 | 2011 | 6 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1039 | 0.100 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2011 | 14 | 0.100 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 40 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 865 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2010 | 157 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 173 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 595 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 995 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 779 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2010 | 272 | 0.080 |
Why?
|
| Time Factors | 2 | 2021 | 5319 | 0.080 |
Why?
|
| Male | 10 | 2021 | 42006 | 0.080 |
Why?
|
| Obesity | 2 | 2014 | 972 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 158 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2010 | 686 | 0.070 |
Why?
|
| Cross Infection | 1 | 2007 | 146 | 0.070 |
Why?
|
| Cell Line | 1 | 2010 | 2498 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 2746 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 3444 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2538 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2010 | 1645 | 0.060 |
Why?
|
| Mastectomy | 2 | 2016 | 245 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2014 | 4271 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 98 | 0.050 |
Why?
|
| Respiration | 2 | 2018 | 266 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2018 | 1542 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2016 | 774 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1843 | 0.050 |
Why?
|
| Prone Position | 1 | 2020 | 56 | 0.050 |
Why?
|
| Uterus | 1 | 2021 | 221 | 0.040 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2019 | 8 | 0.040 |
Why?
|
| Women's Rights | 1 | 2019 | 7 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 22 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2014 | 770 | 0.040 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 48 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 79 | 0.040 |
Why?
|
| Spirometry | 1 | 2018 | 67 | 0.040 |
Why?
|
| Vincristine | 1 | 2018 | 112 | 0.040 |
Why?
|
| Survival Rate | 2 | 2013 | 1883 | 0.040 |
Why?
|
| Prednisone | 1 | 2018 | 258 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 299 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2019 | 184 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2018 | 298 | 0.040 |
Why?
|
| Kinetics | 1 | 2019 | 1530 | 0.040 |
Why?
|
| Risk Factors | 2 | 2019 | 5449 | 0.040 |
Why?
|
| Pelvis | 1 | 2016 | 94 | 0.030 |
Why?
|
| Nitriles | 1 | 2016 | 160 | 0.030 |
Why?
|
| Fatigue | 1 | 2016 | 178 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 390 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2014 | 7 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 3654 | 0.030 |
Why?
|
| Rotation | 1 | 2014 | 91 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 172 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2016 | 372 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2013 | 3676 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 115 | 0.030 |
Why?
|
| Acute Disease | 1 | 2015 | 838 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1716 | 0.030 |
Why?
|
| Chicago | 1 | 2016 | 1411 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1051 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 947 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 200 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 369 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1592 | 0.020 |
Why?
|
| Vinblastine | 1 | 2010 | 108 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 902 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 594 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 226 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2019 | 1037 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2019 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 329 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 304 | 0.020 |
Why?
|
| Child | 2 | 2013 | 7086 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 559 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1648 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1851 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1756 | 0.020 |
Why?
|
| Adolescent | 2 | 2013 | 9156 | 0.020 |
Why?
|
| Esthetics | 1 | 2007 | 45 | 0.020 |
Why?
|
| Pakistan | 1 | 2007 | 15 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2007 | 75 | 0.020 |
Why?
|
| Movement | 1 | 2007 | 307 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 858 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2007 | 389 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 2406 | 0.010 |
Why?
|